Zhou et al. Phase 2 RCT of XKH004, IL17A/Fi in AxSpA. ASAS40 50.4% vs 25%. Slightly odd dose response variation, but may

Social Author Image

https://pbs.twimg.com/profile_images/1389468430160510976/sooz0Ud3_normal.jpg

Tweet Author

Social Author Name

Richard Conway

Tweet Content

Zhou et al. Phase 2 RCT of XKH004, IL17A/Fi in AxSpA. ASAS40 50.4% vs 25%. Slightly odd dose response variation, but maybe just noise. @RheumNow #ACR24 Abstr#1453 https://t.co/SsTSThFzro https://t.co/C9yK2G4tqB

Links

Efficacy and Safety of the Recombinant Anti-human IL-17A/F Humanized Monoclonal… https://acrabstracts.org/abstract/efficacy-and-safety-of-the-recombinant-anti-h…

https://x.com/RichardPAConway/status/1858185580116328614/photo/1

Show on Archive Page

On

Display in Search Results

On

PDQ

Off

Topics

Zhou et al. Phase 2 RCT of XKH004, IL17A/Fi in AxSpA. ASAS40 50.4% vs 25%. Slightly odd dose response variation, but may

Do you get our email newsletter?